– UK, Oxford – Physiomics plc (LON: PYC) today announced the appointment of Shalabh Kumar to its board as an Independent Non-Executive Director with immediate effect.
“We are delighted that Shalabh has agreed to join the Company as an Independent Non-Executive Director. Shalabh has impressive business acumen within the life sciences sector and has overseen the successful implementation of growth strategies at a number of companies. We look forward to working alongside Shalabh in the future and welcome the insight he can provide to Physiomics.” said CEO, Dr. Jim Millen.
About Shalabh Kumar
Mr. Shalabh Kumar is a proven business executive with over 30 years of experience within the life sciences consulting and services industry. Shalabh co-founded, and subsequently was CEO of Kinapse, life sciences consulting and outsourcing service provider, which was later acquired by Syneos Health® (Nasdaq: SYNH) after growing to employ over 600 people across the UK, India, and the US. Before that, he worked for Accenture, Gillette (Procter & Gamble), and Unilever. More recently, Shalabh has worked as an independent strategy consultant and angel investor in the life sciences industry, working with biopharmaceutical companies, life sciences services and technology companies, and private equity firms. Mr. Kumar’s recent roles include Chairman of the Board of Clustermarket Ltd, a lab software start-up; independent strategy consultant to the life sciences R&D group of Accenture plc (NYSE: ACN); and Global Head of Services at Navitas Life Sciences, a technology-backed life sciences contract research organization.
About Physiomics
Physiomics plc is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalized medicine solutions. The Company’s Virtual Tumour™ technology uses computer modeling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies has been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co, and Bicycle Therapeutics.
For more information: https://www.physiomics.co.uk/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
